Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spartalizumab vs Chemotherapy in Advanced Nasopharyngeal Carcinoma
NCT02605967Phase 2Completed
- Sponsor
- Novartis
- Start
- Apr 2016
- Primary completion
- Nov 2019
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 7
01
Overview
A Phase 2 trial of spartalizumab in nasopharyngeal carcinoma (NPC), sponsored by Novartis. Started Apr 2016; status: completed.
02
Drugs
spartalizumab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT02605967.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02605967.